Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Bio-Techne (NASDAQ: TECH) has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting from April 25-30 in Chicago. The company will showcase its oncology research portfolio at two booths:
At booth #3049, Bio-Techne will display its comprehensive portfolio including proteins, antibodies, cell culture reagents, and spatial multiomic solutions. Advanced Cell Diagnostics (ACD) will feature its RNAscope™ spatial portfolio and host an evening reception on April 27th.
At booth #3249, Lunaphore will present its spatial biology solutions, including a new fully-automated, same-section multiomics application for fixed-frozen tissue. The company will host a dinner reception on April 28th to showcase its HORIZON™ image analysis software.
The company will also present multiple scientific posters covering topics such as protein quantitation, biomarker evaluation, and spatial multiomics analysis in cancer research.
Bio-Techne (NASDAQ: TECH) ha annunciato la sua partecipazione all'Annual Meeting 2025 dell'American Association for Cancer Research (AACR), che si terrà dal 25 al 30 aprile a Chicago. L'azienda presenterà il suo portfolio di ricerca oncologica in due stand:
Presso lo stand #3049, Bio-Techne esporrà il suo ampio portfolio che include proteine, anticorpi, reagenti per colture cellulari e soluzioni spaziali multiomiche. Advanced Cell Diagnostics (ACD) presenterà il suo portfolio spaziale RNAscope™ e organizzerà un ricevimento serale il 27 aprile.
Allo stand #3249, Lunaphore presenterà le sue soluzioni di biologia spaziale, inclusa una nuova applicazione multiomica completamente automatizzata e su sezione unica per tessuti fissati e congelati. L'azienda ospiterà una cena il 28 aprile per mostrare il software di analisi delle immagini HORIZON™.
Inoltre, l'azienda presenterà diversi poster scientifici su temi quali la quantificazione delle proteine, la valutazione dei biomarcatori e l'analisi multiomica spaziale nella ricerca sul cancro.
Bio-Techne (NASDAQ: TECH) ha anunciado su participación en la Reunión Anual 2025 de la American Association for Cancer Research (AACR), que se celebrará del 25 al 30 de abril en Chicago. La compañía mostrará su portafolio de investigación oncológica en dos stands:
En el stand #3049, Bio-Techne exhibirá su completo portafolio que incluye proteínas, anticuerpos, reactivos para cultivo celular y soluciones espaciales multiómicas. Advanced Cell Diagnostics (ACD) presentará su portafolio espacial RNAscope™ y organizará una recepción nocturna el 27 de abril.
En el stand #3249, Lunaphore presentará sus soluciones de biología espacial, incluyendo una nueva aplicación multiómica totalmente automatizada y en la misma sección para tejido fijado y congelado. La compañía ofrecerá una cena el 28 de abril para mostrar su software de análisis de imágenes HORIZON™.
Además, la empresa presentará varios pósteres científicos sobre temas como cuantificación de proteínas, evaluación de biomarcadores y análisis multiómico espacial en la investigación del cáncer.
Bio-Techne (NASDAQ: TECH)는 2025년 4월 25일부터 30일까지 시카고에서 열리는 미국암연구학회(AACR) 연례회의에 참가한다고 발표했습니다. 회사는 두 개의 부스에서 종양학 연구 포트폴리오를 선보일 예정입니다:
부스 #3049에서는 Bio-Techne가 단백질, 항체, 세포 배양 시약 및 공간 다중오믹스 솔루션을 포함한 종합 포트폴리오를 전시합니다. Advanced Cell Diagnostics(ACD)는 RNAscope™ 공간 포트폴리오를 선보이며 4월 27일 저녁 리셉션을 개최합니다.
부스 #3249에서는 Lunaphore가 고정-냉동 조직을 위한 완전 자동화된 동일 섹션 다중오믹스 애플리케이션을 포함한 공간 생물학 솔루션을 발표합니다. 회사는 4월 28일 저녁 만찬을 주최하며 HORIZON™ 이미지 분석 소프트웨어를 소개합니다.
또한 회사는 단백질 정량, 바이오마커 평가 및 암 연구에서 공간 다중오믹스 분석과 같은 주제를 다룬 여러 과학 포스터를 발표할 예정입니다.
Bio-Techne (NASDAQ : TECH) a annoncé sa participation à la réunion annuelle 2025 de l'American Association for Cancer Research (AACR), qui se tiendra du 25 au 30 avril à Chicago. L'entreprise présentera son portefeuille de recherche en oncologie sur deux stands :
Au stand n°3049, Bio-Techne exposera son portefeuille complet comprenant des protéines, des anticorps, des réactifs pour culture cellulaire et des solutions multi-omiques spatiales. Advanced Cell Diagnostics (ACD) présentera son portefeuille spatial RNAscope™ et organisera une réception le soir du 27 avril.
Au stand n°3249, Lunaphore présentera ses solutions de biologie spatiale, incluant une nouvelle application multi-omique entièrement automatisée sur la même section pour tissus fixés congelés. L'entreprise organisera un dîner le 28 avril pour mettre en avant son logiciel d’analyse d’images HORIZON™.
L'entreprise présentera également plusieurs posters scientifiques couvrant des sujets tels que la quantification des protéines, l’évaluation des biomarqueurs et l’analyse multi-omique spatiale dans la recherche sur le cancer.
Bio-Techne (NASDAQ: TECH) hat seine Teilnahme am Jahreskongress 2025 der American Association for Cancer Research (AACR) angekündigt, der vom 25. bis 30. April in Chicago stattfindet. Das Unternehmen wird sein Portfolio zur Krebsforschung an zwei Ständen präsentieren:
Am Stand #3049 zeigt Bio-Techne sein umfassendes Portfolio, darunter Proteine, Antikörper, Zellkultur-Reagenzien und räumliche Multiomik-Lösungen. Advanced Cell Diagnostics (ACD) wird sein RNAscope™-räumliches Portfolio vorstellen und am 27. April einen Abendempfang ausrichten.
Am Stand #3249 präsentiert Lunaphore seine Lösungen zur räumlichen Biologie, darunter eine neue vollautomatisierte Multiomik-Anwendung auf derselben Gewebesektion für fixiertes und gefrorenes Gewebe. Das Unternehmen veranstaltet am 28. April ein Abendessen, um seine HORIZON™ Bildanalysesoftware vorzustellen.
Zusätzlich wird das Unternehmen mehrere wissenschaftliche Poster zu Themen wie Proteinquantifizierung, Biomarkerevaluierung und räumlicher Multiomikanalyse in der Krebsforschung präsentieren.
- None.
- None.
AACR is recognized as one of the world's most influential cancer research conferences, convening global experts to exchange groundbreaking discoveries and innovations in cancer science and medicine. Bio-Techne will engage with these researchers and industry professionals to highlight its cutting-edge solutions that empower scientific progress across the oncology landscape.
At booth #3049, Bio-Techne will feature its comprehensive portfolio, including high-performance proteins, antibodies, small molecules, cell culture reagents, immunoassays, automated proteomic analysis platforms, and spatial multiomic solutions. These technologies are designed to drive advancements in oncology research, accelerate immune cell therapy development, and support the creation of next-generation diagnostic tools. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will feature its complete solution for accelerating spatial multiomic research, including its protease-free workflows across the RNAscope™ spatial portfolio. To support the expanded capabilities for multiomic detection on the Leica Bond RX, we will showcase scientific posters and an evening reception on April 27th co-hosted by ACD, Leica Biosystems and Indica Labs.
At booth #3249, Lunaphore, one of Bio-Techne's spatial biology brands, will present its enhanced end-to-end portfolio that offers high-value spatial biology solutions for the translational research community. Lunaphore's latest advancements include the launch of the fully-automated, same-section multiomics application for fixed-frozen tissue. Additionally, Lunaphore will bring together the spatial biology community at an exclusive dinner reception on April 28, held in affiliation with AACR, providing a unique opportunity to connect with leaders in the field of multiomics, and explore Lunaphore's upcoming releases, including innovative tools for HORIZON™ image analysis software.
"As cancer research advances at an unprecedented pace, Bio-Techne remains committed to providing scientists with the tools they need to drive discovery and innovation," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "Our solutions empower researchers at every stage—from fundamental science to translational applications—helping to shape the future of precision medicine and next-generation cancer therapies. We are excited to connect with the scientific community at AACR to explore new possibilities in the fight against cancer."
Bio-Techne Presentations and Poster Presentations:
Protein Quantitation for Characterization of Potential Cancer Therapeutics in Early Discovery and Mechanism of Action Insights in Translational Studies
Tuesday, April 29 | 10:00 – 11:00 AM
Exhibit Hall, Spotlight Theater A
Evaluation of IDH1, EGFR, IGF1R, and Ki67 Biomarkers in Glioblastoma Using Lunaphore COMET™ Platform
Monday, April 28 | 9:00 AM - 12:00 PM
Poster Board 29 | Abstract 2093
Presenter: Jennifer Jones, Sr. Product Marketing Specialist
Multiomic Co-Detection of Proteins, mRNA and Protein-Protein Interactions Reveal PD1-PDL1 Interactions in the Tumor Microenvironment of Bladder Cancer Patients Treated with anti-PD-L1
Monday, April 28 | 9:00 AM - 12:00 PM
Poster Board 3 | Abstract 2179
Presenter: Ge-Ah Kim, Sr. Scientist
Multiomic Fluorescent Co-Detection of Biomarkers in the Tumor Microenvironment Using a New RNAscope™ Assay on Roche DISCOVERY™ ULTRA
Monday, April 28 | 9:00 AM - 12:00 PM
Poster Board 28 | Abstract 2092
Presenter: Anushka Dikshit, Sr. Applications Manager
Identifying Immune Cell Phenotypes and Their Function by Using High Throughput Spatial Multiomics
Tuesday, April 29 | 2:00 PM - 5:00 PM
Poster Board 24 | Abstract 5318
Presenter: Anushka Dikshit, Sr. Applications Manager
Profiling the Tumor-Immune Landscape with a Same-Section Multiomics Assay
Tuesday, April 29 | 2:00 PM - 5:00 PM
Poster Board 10 | Abstract 5304
Presenter: Jacqueline Giliberti, PhD, Product Manager
Spatial Multiomics Reveals T-cell Activation and Exhaustion States in the Tumor Microenvironment
Wednesday, April 30 | 9:00 AM - 12:00 PM
Poster Board 12 | Abstract 6471
Presenter: Anushka Dikshit, Sr. Applications Manager
Poster Presentation In Collaboration
A Novel Protease-Free Workflow for Spatial Multiomics Analysis of the Tumor Microenvironment in Breast Cancer
Poster Board 21 | Abstract 170
Presenter: Dr. Tanni Rahman, HistoWiz
Dissecting the Immune Landscape in EBV+ Classical Hodgkin Lymphoma Following IL-23 Inhibition Using Single-Cell Hyperplex Immunofluorescence Analysis: A Case Report
Wednesday, April 30 | 9:00 AM - 12:00 PM
Poster Board 9 | Abstract 6468
Presenter: Dr. Janusz Franco-Barraza, Fox Chase Cancer Center
Translating clinically Validated Antibodies into a Multiplexed Immunofluorescent Panel for the Spatial Profiling of Lymphoid Malignancies
Monday, April 28 | 2:00 PM - 5:00 PM
Poster Board 4 | Abstract 2525
Presenter: Dr. Tania Pannellini, European Institute of Oncology (EIO)
For more information about Bio-Techne's presence at AACR 2025, visit https://www.bio-techne.com/about/events/aacr.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-showcase-cutting-edge-solutions-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting-302435787.html
SOURCE Bio-Techne Corporation
FAQ
What new technologies will Bio-Techne (TECH) showcase at AACR 2025?
When and where is Bio-Techne (TECH) presenting at AACR 2025?
What are the key events Bio-Techne (TECH) is hosting during AACR 2025?
How many research posters will Bio-Techne (TECH) present at AACR 2025?
